Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$12,585 | -$20,340 | -$25,120 | -$23,113 |
| Dep. & Amort. | $400 | $453 | $460 | $432 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $12,243 | $8,233 | $6,930 | $7,403 |
| Change in WC | $19,328 | -$16,355 | -$1,910 | -$5,727 |
| Other Non-Cash | -$1,129 | -$1,378 | -$1,011 | -$1,177 |
| Operating Cash Flow | $18,257 | -$29,387 | -$20,651 | -$22,182 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,910 | -$1,001 | -$590 | -$72 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$102,333 | -$129,703 | -$125,570 | -$89,967 |
| Inv. Sales/Matur. | $99,500 | $79,000 | $91,218 | $35,465 |
| Other Inv. Act. | $0 | $0 | $0 | -$5,000 |
| Investing Cash Flow | -$4,743 | -$51,704 | -$34,942 | -$59,574 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | -$31,877 |
| Stock Issued | $2,562 | $1,952 | $136,562 | $2,927 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $31,877 |
| Financing Cash Flow | $2,562 | $1,952 | $136,562 | $2,927 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $16,076 | -$79,139 | $80,969 | -$78,829 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $99,211 | $178,350 | $97,381 | $176,210 |
| End Cash | $115,287 | $99,211 | $178,350 | $97,381 |
| Free Cash Flow | $16,347 | -$30,388 | -$21,241 | -$27,254 |